Search results
There have been reports for medication errors possibly leading to lack of effect with all leuprorelin containg products. For one product (Eligard) there have been 2,271 cases of handling errors reported
3 cze 2022 · The development of second-generation leuprorelin acetate (LA) depot formulation (Eligard®, Recordati S.p.A) allowed a consistent and controlled release of leuprorelin between injections and a more efficient reduction of testosterone levels with respect to conventional LHRH agonists.
Leuprorelin-containing depot medicinal products are indicated for prostate cancer, breast cancer and conditions that affect the female reproductive system (e.g. endometriosis, uterine fibroids) and early puberty.
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine (s). It also includes a communication plan with details of intended recipients and the dissemination date.
Leuprorelin-containing depot products are used as an alternative to surgical castration in metastatic prostate cancer and locally advanced prostate cancer. They are also used as adjuvant hormone
In humans, administration of leuprorelin acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in
Medical use. Leuprorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer. It may also be used for estrogen-dependent conditions such as endometriosis [13] or uterine fibroids.
